In fiscal year 2024, the institution rate for bio/pharma IPR petitions was approximately 73%, and of those instituted, a substantial fraction resulted in cancellation of at least some challenged claims
Buying from an unverifiable supplier with no batch traceability leaves a practitioner unable to answer the most basic clinical governance question if something goes wrong: what, exactly, did the patient receive
On the contrary, orforglipron (RR 1.4640 [95% CI 0.2619, 8.1832
Por eso, en nuestro catlogo diferenciamos las dos formas principales de este suplemento: Consulta nuestro catlogo, aade tu producto de carnitina preferido al carrito de la compra y completa tu pedido
According to a statement from BMS, the first generic versions of Eliquis will be blocked from entering until at least April 1, 2028 as a result of the 208 and 945 patents.8 This would mean BMS and Pfizer would have gained nearly six extra years of market monopoly beyond the original expiration of September 17, 2022 for the 208 patent
In Bexar County, people 65 and older make up 12.5% of the population, while more than half of residents are Hispanic
